Publication
P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentr...
O. Caffo, U. De Giorgi, L. Fratino, D. Alesini, U. Basso, G. Facchini, D. Gasparro, C. Ortega, M. Tucci, F. Verderame, E. Campadelli, G. Lo Re, G. Procopio, R. Sabbatini, M. Donini, F. Morelli, D. Sartori, P. Zucali, V. Conteduca, F. Maines, E. Galligioni
European Urology Supplements, November 2014, Elsevier
DOI: 10.1016/s1569-9056(14)61295-1